Search

CN-122012285-A - Lactobacillus rhamnosus LRa05, lactobacillus acidophilus La88 and lactobacillus plantarum Lp90 combination and application thereof in regulating vaginal mucosa barrier protein

CN122012285ACN 122012285 ACN122012285 ACN 122012285ACN-122012285-A

Abstract

The application relates to the field of prevention and treatment of vaginitis, in particular to a combination of lactobacillus rhamnosus LRa05, lactobacillus acidophilus La88 and lactobacillus plantarum Lp90 and application thereof in regulating vaginal mucosa barrier proteins. The lactobacillus rhamnosus LRa05 is lactobacillus rhamnosus (Lactobacillus rhamnosus) LRa05 with the preservation number of CGMCC NO. 24377. The Lactobacillus acidophilus La88 is Lactobacillus acidophilus (Lactobacillus acidophilus) La88 with the preservation number of CGMCC No. 24109. The lactobacillus plantarum Lp90 is lactobacillus plantarum (Lactobacillus plantarum) Lp90 with the preservation number of CGMCC NO. 10453. The lactobacillus rhamnosus LRa05, lactobacillus acidophilus La88 and lactobacillus plantarum Lp90 and the combination thereof disclosed by the application can regulate the vaginal mucosa barrier protein expression.

Inventors

  • FANG SHUGUANG
  • XIANG LIJUAN
  • ZHU MINGMING
  • LI ZHONGLIN
  • CHEN KEKE

Assignees

  • 武汉微康益生菌研究院有限公司
  • 微康益生菌(苏州)股份有限公司

Dates

Publication Date
20260512
Application Date
20260325

Claims (10)

  1. 1. A probiotic preparation comprising at least one of the following: a) At least one or a mixture of a plurality of dead thalli, living thalli, inactivated thalli and metazoan of lactobacillus rhamnosus LRa05 with the preservation number of CGMCC NO. 24377; b) At least one or more of dead thallus, living thallus, inactivated thallus and metazoan of Lactobacillus acidophilus La88 with preservation number of CGMCC No.24109, and C) At least one or a mixture of a plurality of dead thalli, living thalli, inactivated thalli and metazoan of lactobacillus plantarum Lp90 with the preservation number of CGMCC No. 10453.
  2. 2. The probiotic formulation according to claim 1, being a modulator of vaginal mucosal barrier protein, said vaginal mucosal barrier protein being at least one of ZO-1, OCLN, CLDN 1.
  3. 3. The probiotic preparation according to claim 1, which is a bacteriostatic preparation comprising bacteria of the genus alcaligenes.
  4. 4. The probiotic formulation according to claim 1, which is a bacteriostatic formulation comprising gardnerella vaginalis.
  5. 5. The probiotic preparation according to claim 1, being a preparation for reducing the abundance of the proteobacteria flora of the intestinal tract and/or increasing the abundance of the proteobacteria flora of the thick-walled bacteria.
  6. 6. The probiotic preparation according to claim 1, which is an inactivated bacterial agent for controlling the ratio of Proteus/Thick-walled bacteria in an in vitro intestinal flora simulation system.
  7. 7. The probiotic formulation according to claim 1, being a formulation comprising an abundance of alcaligenes in the gut.
  8. 8. The probiotic formulation according to claim 1, which is a formulation that increases the abundance of streptococcus enteriae.
  9. 9. The probiotic preparation according to claim 1, which is a preparation for reducing the activity of inflammatory factors and MPO in vaginal tissue lysates.
  10. 10. Application of at least one of lactobacillus rhamnosus LRa05 with the preservation number of CGMCC No.24377, lactobacillus acidophilus La88 with the preservation number of CGMCC No.24109 and lactobacillus plantarum Lp90 with the preservation number of CGMCC No.10453, wherein the application comprises: preparing a regulating preparation of vaginal mucosa barrier protein; preparing a bacteriostatic formulation comprising a bacterium of the genus alcaligenes; Preparing a bacteriostatic formulation comprising a bacterium that is specific to ganacola vaginalis; preparing a preparation for reducing the abundance of the proteobacteria flora of the intestinal canal and/or improving the abundance of the proteobacteria flora of the thick wall; preparing an inactivated thallus reagent for regulating and controlling the ratio of the Proteus to the Thick-walled bacteria in an in-vitro intestinal flora simulation system; Preparing a formulation that reduces abundance of alcaligenes contained in the gut; preparing a preparation for increasing the abundance of streptococcus enteriae; Preparing a preparation for reducing the inflammatory factor and MPO activity of vaginal tissue lysate.

Description

Lactobacillus rhamnosus LRa05, lactobacillus acidophilus La88 and lactobacillus plantarum Lp90 combination and application thereof in regulating vaginal mucosa barrier protein Technical Field The application relates to the field of mechanical barrier function regulation of vaginal mucosa, in particular to a combination of lactobacillus rhamnosus LRa05, lactobacillus acidophilus La88 and lactobacillus plantarum Lp90 and application thereof in regulating vaginal mucosa barrier protein. Background The mechanical barrier function of the vaginal mucosa is a central basis for maintaining the health of the female reproductive system, and its structural integrity and functional stability are directly dependent on the normal expression of the intercellular tight junctions proteins of the epithelium. For example, three key proteins, namely, closed small ring protein 1 (ZonulaOccludens-1, ZO-1), closed protein (Occludin, OCLN) and Claudin-1 protein (Claudin-1, CLDN1), reduce vaginal epithelial permeability and prevent invasion of external harmful substances by forming a cell-cell tight junction complex, and the expression level and functional state directly determine the defensive capacity of the vaginal mucosal barrier. Lactobacillus rhamnosus (Lactobacillusreuteri) and lactobacillus acidophilus (Lactobacillus acidophilus) have been shown in the prior art to be involved in reproductive health protection by regulating vaginal flora structure, maintaining the acidic environment of the vagina, and the like. However, lactobacillus rhamnosus and lactobacillus acidophilus are not found to directly regulate the vaginal mucosa tight junction proteins ZO-1, OCLN and CLDN1, and the regulation and control effects and mechanisms of the vaginal mucosa mechanical barrier are not clear. Meanwhile, the functional localization of the existing probiotics products is mostly concentrated on 'flora balance adjustment' or 'mucosa adhesion field planting', and the accurate design for 'vaginal epithelium tight junction protein expression regulation' is lacking, so that the directional enhancement of the mechanical barrier function of the vaginal mucosa can not be realized. Disclosure of Invention The application provides a probiotic preparation, which comprises at least one of the following components: a) At least one or a mixture of a plurality of dead thalli, living thalli, inactivated thalli and metazoan of lactobacillus rhamnosus LRa05 with the preservation number of CGMCC NO. 24377; b) At least one or more of dead thallus, living thallus, inactivated thallus and metazoan of Lactobacillus acidophilus La88 with preservation number of CGMCC No.24109, and C) At least one or a mixture of a plurality of dead thalli, living thalli, inactivated thalli and metazoan of lactobacillus plantarum Lp90 with the preservation number of CGMCC No. 10453. In some embodiments, the probiotic formulation is a modulating formulation of a vaginal mucosal barrier protein that is at least one of ZO-1, OCLN, CLDN 1. In some embodiments, the probiotic formulation is a bacteriostatic formulation comprising bacteria of the genus alcaligenes. In some embodiments, the probiotic formulation is a bacteriostatic formulation comprising gardnerella vaginalis. In some embodiments, the probiotic formulation is a formulation that reduces the abundance of the proteobacteria population of the enteromorpha and/or increases the abundance of the trichobacteria population of the firmicutes. In some embodiments, the probiotic preparation is an inactivated bacterial agent for use in an in vitro intestinal flora simulation system for controlling the ratio of proteus/firmicutes. In some embodiments, the probiotic formulation is a formulation that reduces the abundance of alcaligenes contained in the gut. In some embodiments, the probiotic formulation is a formulation that increases the abundance of streptococcus enteriae. In some embodiments, the probiotic formulation is a formulation that reduces the activity of inflammatory factors and MPO in vaginal tissue lysates. The application also provides application of at least one of lactobacillus rhamnosus LRa05 with the preservation number of CGMCC No.24377, lactobacillus acidophilus La88 with the preservation number of CGMCC No.24109 and lactobacillus plantarum Lp90 with the preservation number of CGMCC No.10453, wherein the application comprises: preparing a regulating preparation of vaginal mucosa barrier protein; preparing a bacteriostatic formulation comprising a bacterium of the genus alcaligenes; Preparing a bacteriostatic formulation comprising a bacterium that is specific to ganacola vaginalis; preparing a preparation for reducing the abundance of the proteobacteria flora of the intestinal canal and/or improving the abundance of the proteobacteria flora of the thick wall; preparing an inactivated thallus reagent for regulating and controlling the ratio of the Proteus to the Thick-walled bacteria in an in-vitro intestinal flora sim